A Novel Humanized Anti-Abrin A Chain Antibody Inhibits Abrin Toxicity In Vitro and In Vivo

被引:1
|
作者
Peng, Jingyi [1 ,2 ]
Wu, Jiaguo [2 ,3 ]
Shi, Ning [2 ,4 ]
Xu, Hua [2 ]
Luo, Longlong [2 ]
Wang, Jing [2 ]
Li, Xinying [2 ]
Xiao, He [2 ]
Feng, Jiannan [2 ]
Li, Xia [1 ]
Chai, Lihui [1 ]
Qiao, Chunxia [2 ,5 ]
机构
[1] Henan Univ, Affiliated Hosp 1, Sch Med, Joint Natl Lab Antibody Drug Engn, Kaifeng, Peoples R China
[2] Acad Mil Med Sci, Acad Mil Med Sci, Inst Pharmacol & Toxicol, State key Lab Toxicol & Med Countermeasures, Beijing, Peoples R China
[3] Dali Univ, Sch Basic Med Sci, Dept Anat, Dalian, Peoples R China
[4] Cent South Univ, Sch Basic Med Sci, Canc Res Inst, Changsha, Peoples R China
[5] Henan Univ, Sch Pharm, Kaifeng, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
abrin; humanization; neutralizing antibody; protective effect; computer-aided design; RIBOSOME-INACTIVATING PROTEINS; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; RICIN; PROTECTION; TOXIN;
D O I
10.3389/fimmu.2022.831536
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Abrin, a type-II ribosome inactivating protein from the seed of Abrus precatorius, is classified as a Category B bioterrorism warfare agent. Due to its high toxicity, ingestion by animals or humans will lead to death from multiple organ failure. Currently, no effective agents have been reported to treat abrin poisoning. In this study, a novel anti-abrin neutralizing antibody (S008) was humanized using computer-aided design, which possessed lower immunogenicity. Similar to the parent antibody, a mouse anti-abrin monoclonal antibody, S008 possessed high affinity and showed a protective effect against abrin both in vitro and in vivo, and protected mice that S008 was administered 6 hours after abrin. S008 was found that it did not inhibit entry of abrin into cells, suggesting an intracellular blockade capacity against the toxin. In conclusion, this work demonstrates that S008 is a high affinity anti-abrin antibody with both a neutralizing and protective effect and may be an excellent candidate for clinical treatment of abrin poisoning.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] IN-VITRO AND IN-VIVO ANTITUMOR-ACTIVITY OF A CHIMERIC ANTI-CD19 ANTIBODY
    PIETERSZ, GA
    LI, WJ
    SUTTON, VR
    BURGESS, J
    MCKENZIE, IFC
    ZOLA, H
    TRAPANI, JA
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1995, 41 (01) : 53 - 60
  • [42] In vitro and in vivo investigation of a novel monoclonal antibody to plasma cells (W5 mAb)
    Harper, D
    Gollackner, B
    Xu, Y
    Calderhead, D
    Ryan, D
    Li, W
    Chang, J
    Wu, C
    Moran, K
    Latinne, D
    Bazin, H
    White-Scharf, ME
    Cooper, DKC
    Awwad, M
    XENOTRANSPLANTATION, 2004, 11 (01) : 78 - 90
  • [43] A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM)
    Anja Kathrin Wege
    Nicole Kirchhammer
    Linda Veronique Kazandjian
    Sandra Prassl
    Michael Brandt
    Gerhard Piendl
    Olaf Ortmann
    Stephan Fischer
    Gero Brockhoff
    Journal of Translational Medicine, 18
  • [44] A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM)
    Wege, Anja Kathrin
    Kirchhammer, Nicole
    Kazandjian, Linda Veronique
    Prassl, Sandra
    Brandt, Michael
    Piendl, Gerhard
    Ortmann, Olaf
    Fischer, Stephan
    Brockhoff, Gero
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)
  • [45] Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo
    Chang, De-Kuan
    Moniz, Raymond J.
    Xu, Zhongyao
    Sun, Jiusong
    Signoretti, Sabina
    Zhu, Quan
    Marasco, Wayne A.
    MOLECULAR CANCER, 2015, 14
  • [46] Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity
    Boland, William Kells
    Bebb, Gwyn
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (09) : 1199 - 1206
  • [48] A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo
    Ward, Elizabeth
    Mittereder, Nanette
    Kuta, Ellen
    Sims, Gary P.
    Bowen, Michael A.
    Dall'Acqua, William
    Tedder, Thomas
    Kiener, Peter
    Coyle, Anthony J.
    Wu, Herren
    Jallal, Bahija
    Herbst, Ronald
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 155 (04) : 426 - 437
  • [49] A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo
    Desombere, Isabelle
    Mesalam, Ahmed Atef
    Urbanowicz, Richard A.
    Van Houtte, Freya
    Verhoye, Lieven
    Keck, Zhen-Yong
    Farhoudi, Ali
    Vercauteren, Koen
    Weening, Karin E.
    Baumert, Thomas F.
    Patel, Arvind H.
    Foung, Steven K. H.
    Ball, Jonathan
    Leroux-Roels, Geert
    Meuleman, Philip
    ANTIVIRAL RESEARCH, 2017, 148 : 53 - 64
  • [50] Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124):: in vitro and in vivo studies
    Bolognesi, A
    Tazzari, PL
    Olivieri, F
    Polito, L
    Lemoli, R
    Terenzi, A
    Pasqualucci, L
    Falini, B
    Stirpe, F
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 (01) : 179 - 188